Finance

Enchira Biotechnology Reports Third Quarter Results

Published in Cancer Weekly, December 18th, 2001

Enchira Biotechnology Corp. (ENBC) has announced financial results for the quarter ended September 30, 2001. Revenues for the third quarter were $125,000 compared with $135,157 for the same period in 2000.

Enchira recorded a net loss for the quarter ended September 30, 2001 of $2,466,133, or $0.31 per share compared with $1,577,064 for the same quarter in 2000, or $0.28 per share. This increased net loss was mainly due to amounts owed as a result of the arbitration with Maxygen. On November 3, 2001, the arbitrator issued a final ruling requiring Enchira to pay a portion of Maxygen's attorneys' fees in the amount of $556,826 and the arbitration costs in the amount of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry